Skip to main content

Apadaz News

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) – KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today...

FDA Approves Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) – KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Pain

Apadaz patient information at Drugs.com